Phase II

AVL-292

Description:

AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia


Type(s) of Cancer: Leukemia/Blood/Hematologic
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

AVL-292

Description:

AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia


Type(s) of Cancer: Lymphoma
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

Cetuximab+Docetaxel+Cisplatin+Bevacizumab+XRT

Description:

This Phase II study of cetuximab in combination with docetaxel, cisplatin, bevacizumab and radiation in patients with locally advanced head and neck cancer. Cetuximab binds to epidermal growth factor receptor and blocks the activity of epidermal growth factor.


Type(s) of Cancer: Head and Neck
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

CFG920

Description:

CFG920 is a non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 with potential antiandrogen and antineoplastic activities. In this Phase I/II study CFG920 will be administered orally in patients with metastatic castration-resistant prostate cancer after progressing (or have refused) on Abiraterone and Docetaxel.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

G 202

Description:

G-202 is a pro-drug, consisting of cytotoxic analog of thapsigargin and a peptide to activate it at the tumor site. It is administered by intravenous infusion daily for 3 consecutive days on a 28 day cycle in patients with advanced hepatocellular carcinoma after progression on Sorafenib therapy.


Type(s) of Cancer: Liver
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

M402

Description:

M402 is a heparin sulfate mimetic designed to have antitumor effect without the anticoagulant activity. In this Phase I/II study M402 is administered as daily subcutaneous injection with Gemcitabine in patients with metastatic pancreatic cancer who have not received prior chemotherapy.


Type(s) of Cancer: Pancreas
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

Metformin

Description:

Metformin is widely used anti-diabetic medicine. It can also act as an anti-cancer agent by activation of AMP-activated protein kinase (AMPK) pathway and subsequent inhibition of mTOR that blocks the cancer cell growth and proliferation. It may also lessen the symptoms of metabolic syndrome caused by androgen deprivation therapy. In this Phase II study patients with advanced prostate cancer will be randomly selected to receive castration only or castration plus metformin as first line treatment.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

Nexrutine in Prostrate Cancer Patients Undergoing Surgery or Radiation Therapy (only open to veterans)

Description:

For veterans only; Patients will take Nexrutine® (an oral dietary supplement) prior to and during radiation treatment for prostate cancer or prior to surgery for prostate cancer. The purpose of the study is to see whether taking Nexrutine® will cause the PSA (Prostate Specific Antigen) to decline.


Type(s) of Cancer: Prostate Cancer
Study Phase(s): Phase II
Contact: Carol Jenkins at (210) 450-5924

RTOG 0913

Description:

Description: This is a Phase I/II study of RAD001 (everolimus) for patients with glioblastoma or gliosarcoma (brain tumor). Patients are randomized to receive RAD 001 with the standard treatment of radiation plus temozolomide (oral chemotherapy) or to receive the standard treatment of radiation plus temozolomide alone.


Type(s) of Cancer: Brain
Study Phase(s): Phase II
Contact: Carol Jenkins at (210) 450-5924

SAHA+Hydroxychloroquine

Description:

SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors


Type(s) of Cancer: Colon Cancer
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

SAHA+Hydroxychloroquine

Description:

SAHA is a HDAC inhibitor. SAHA may also block angiogenic signaling by inhibiting the VEGF receptors expression and also reduce circulating levels of inflammatory cytokines. In this study SAHA is administered with Hydroxychloroquine in patients with advanced solid tumors


Type(s) of Cancer: Kidney
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

TH-302

Description:

TH-302 is a drug that is inert unless activated by enzymes present under low oxygen condition. As many cancer types have low oxygen supply due to the rapid consumption by tumor cells, TH-302 is then broken down in these tumors to its active form which then can kill cancer cells. TH-302 will be administrated on days 1 and 15 with Bevacizumab in patients with recurrent high grade astrocytoma following progression with combined treatment with radiation and temozolomide and also after anti-angiogenic treatment.


Type(s) of Cancer: Brain
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

VB-111

Description: VB-111 is a gene therapy against tumor blood vessels. It consists of a modified cold virus (Adenovirus) which delivers an endothelial angiogenic-specific promoter and a pro-apoptotic Fas Chimera transgene. It targets the growing blood vessels within the tumor to cause their destruction. VB-111 is administered as a single intravenous infusion in patients with glioblastoma multiforme who have disease progression or recurrence following standard of care treatment with Temozolomide and radiation.
Type(s) of Cancer: Brain
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798